Clinical efficacy of Bonton capsule in the treatment of Osteoporosis

Evaluation of clinical efficacy and safety of BONTON capsule in the treatment of Osteoporosis

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020465

Enrollment

Registered

2019-07-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M810- Age-related osteoporosis without current pathological fracture

Interventions

Intervention1: Bonton Capsule: TEST DRUG, DOSE AND DURATION: Test Drug: Bonton Capsule Dose: 2 capsules twice a day, after meal Vehicle: Normal drinking water Route of administration: Oral Duration

Eligibility

Inclusion criteria

Inclusion criteria: (1) Osteopenic/osteoporotic patients of either sex whose BMD (t score) is equal to or less than -1 will be selected for the present study. (2) Patients between the age group of 40 and 70 years and willing to give consent to participate in the study

Exclusion criteria

Exclusion criteria: (1) Patients below 40 years and above 70 years (2) Patients whose BMD (t score) is above -1 (3) Patients suffering from any serious liver, kidney and cardiac diseases. (4) Patients having history of any genetic disorders (5) Patients suffering from Rheumatoid or Gouty arthritis

Design outcomes

Primary

Measure	Time frame
Primary outcomes will be effect of drug on subjective and objective parameters of osteoporosisTimepoint: 16 weeks	—

Secondary

Measure	Time frame
Assessment of drug safety, patientâ??s compliance and quality of lifeTimepoint: 20 weeks	—

Countries

India

Contacts

Public ContactDr Prasanna Mogasale

S D M College of Ayurveda, Kuthpady.

pnmogasale73@gmail.com9845212813

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026